US FDA Dismisses Post-Progression Endpoint In Cyramza Lung Cancer Study

 
• By Sue Sutter
  
Two arrows pointed in different directions on a signpost 3D illustration
The US FDA holds a different view from Lilly and the EMA on the utility of PFS2. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers